Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients

被引：0
|
作者：
Kenichi Namba
Toshikatsu Kaburaki
Hidekazu Tsuruga
Yohei Ogawa
Eri Iwashita
Hiroshi Goto
机构：
[1] Hokkaido University,Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine
[2] University of Tokyo School of Medicine,Department of Ophthalmology
[3] Jichi Medical University Saitama Medical Center,Department of Ophthalmology
[4] AbbVie GK,Department of Ophthalmology
[5] Tokyo Medical University,undefined
来源：
Ophthalmology and Therapy | 2022年 / 11卷
关键词：
Adalimumab; Behçet’s Disease; Sarcoidosis; Uveitis; Vogt-Koyanagi-Harada Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1147 / 1161
页数：14
相关论文
共 50 条
  • [1] Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients
    Namba, Kenichi
    Kaburaki, Toshikatsu
    Tsuruga, Hidekazu
    Ogawa, Yohei
    Iwashita, Eri
    Goto, Hiroshi
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (03) : 1147 - 1161
  • [2] Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
    Suhler, Eric B.
    Jaffe, Glenn J.
    Fortin, Eric
    Lim, Lyndell L.
    Merrill, Pauline T.
    Dick, Andrew D.
    Brezin, Antoine P.
    Quan Dong Nguyen
    Thorne, Jennifer E.
    Van Calster, Joachim
    Cimino, Luca
    Adan, Alfredo
    Goto, Hiroshi
    Kaburaki, Toshikatsu
    Kramer, Michal
    Vitale, Albert T.
    Kron, Martina
    Song, Alexandra P.
    Liu, Jianzhong
    Pathai, Sophia
    Douglas, Kevin M.
    Schlaen, Ariel
    Muccioli, Cristina
    Van Velthoven, Mirjam E. J.
    Zierhut, Manfred
    Rosenbaum, James T.
    OPHTHALMOLOGY, 2021, 128 (06) : 899 - 909
  • [3] Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study
    Rie Kanamori
    Shiho Yamane
    Takeshi Seto
    Advances in Therapy, 2021, 38 : 4949 - 4960
  • [4] Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study
    Kanamori, Rie
    Yamane, Shiho
    Seto, Takeshi
    ADVANCES IN THERAPY, 2021, 38 (09) : 4949 - 4960
  • [5] Long-term safety and effectiveness of omalizumab in Japanese paediatric patients with severe allergic asthma: A post-marketing surveillance
    Nakamura, N.
    Kashitani, Y.
    Yoshisue, H.
    Nagasaki, M.
    Sasajima, T.
    ALLERGY, 2020, 75 : 364 - 365
  • [6] Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance
    Kuroishi, Naho
    Watananbe, Asuka
    Sakuma, Ryuta
    Ruzicka, Daniel J.
    Hara, Mitsuyoshi
    PLOS ONE, 2019, 14 (01):
  • [7] Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study
    Sakae Tanaka
    Hideki Mizutani
    Eri Tsuruya
    Ryoko Fukuda
    Kiyoka Kuge
    Naoki Okubo
    Journal of Bone and Mineral Metabolism, 2021, 39 : 463 - 473
  • [8] Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study
    Tanaka, Sakae
    Mizutani, Hideki
    Tsuruya, Eri
    Fukuda, Ryoko
    Kuge, Kiyoka
    Okubo, Naoki
    JOURNAL OF BONE AND MINERAL METABOLISM, 2021, 39 (03) : 463 - 473
  • [9] Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study
    Yamamoto, Fumiko
    Ikeda, Rie
    Ochiai, Kaori
    Hirase, Tetsuaki
    Hayashi, Naoyuki
    Okamura, Tomoo
    DIABETES THERAPY, 2020, 11 (02) : 523 - 533
  • [10] Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study
    Fumiko Yamamoto
    Rie Ikeda
    Kaori Ochiai
    Tetsuaki Hirase
    Naoyuki Hayashi
    Tomoo Okamura
    Diabetes Therapy, 2020, 11 : 523 - 533
12345